文献速递流行病学与生物统计

使用个体化更长生存概率量化治疗效果

Quantifying treatment effects using the personalized chance of longer survival.
PubMed 文献 · Stat Med · 2019-09-09

风险比广泛用于衡量治疗效应,但难以向患者和临床医生直观解释,且仅在风险函数近似成比例时最有意义。作者提出个体化更长生存概率这一新指标,量化一种治疗相比另一种使患者生存更长的概率,并纳入个体特征以直接反映个体化治疗效应。该指标以患者为中心,便于评估亚组,在非成比例风险下仍直观且可临床解释;作者提供了可处理删失生存结局的非参数估计与推断方法,并通过大量模拟研究刻画方法性能,还使用该方法分析了一项大型随机III期临床试验(SWOG S0819)的数据。

要点

  • 提出个体化更长生存概率,量化一种治疗相比另一种使患者生存更长的概率。
  • 该指标纳入个体特征,以患者为中心,便于评估亚组。
  • 提供可处理删失生存结局的非参数估计与推断方法。

核心结论

  • 作者认为个体化更长生存概率直观、可临床解释,且在风险不成比例时仍适用,并以患者为中心便于评估亚组。

研究设计与样本

  • 方法学论文,提出个体化更长生存概率指标,并提供可处理删失生存结局的非参数估计与推断方法。
  • 通过大量模拟研究刻画所提方法的性能。
  • 使用所提方法分析大型随机III期临床试验(SWOG S0819)的数据。

主要发现

  • 风险比广泛用于衡量或概括治疗效应大小,但难以向患者和临床医生有意义地解释,且仅在风险函数随时间近似成比例时最有意义。
  • 个体化更长生存概率量化一种治疗相比另一种使患者生存更长的概率,并纳入个体化特征以直接反映个体化治疗效应。
  • 该指标以患者为中心,便于评估亚组,作者认为其直观且可临床解释,且因估计的是生存延长某一固定时长的概率而编码了治疗效应估计的概率部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The hazard ratio is widely used to measure or to summarize the magnitude of treatment effects, but it is justifiably difficult to interpret in a meaningful way to patients and perhaps for clinicians as well. In addition, it is most meaningful when the hazard functions are approximately proportional over time. We propose a new measure, termed personalized chance of longer survival. The measure, which quantifies the probability of living longer with one treatment over the another, accounts for individualized characteristics to directly address personalized treatment effects. Hence, the measure is patient focused, which can be used to evaluate subgroups easily. We believe it is intuitive to understand and clinically interpretable in the presence of nonproportionality. Furthermore, because it estimates the probability of living longer by some fixed amount of time, it encodes the probabilistic part of treatment effect estimation. We provide nonparametric estimation and inference procedures that can accommodate censored survival outcomes. We conduct extensive simulation studies, which characterize performance of the proposed method, and data from a large randomized Phase III clinical trial (SWOG S0819) are analyzed using the proposed method.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Zhao YQ, Redman MW, LeBlanc ML, et al. Quantifying treatment effects using the personalized chance of longer survival. Stat Med. 2019. PMID: 31502297. doi:10.1002/sim.8363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。